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Abstract  
Background: Generic substitution (GS), is a cost-containment strategy meant to contain pharmaceutical expenditure without 
compromising health objectives. In order to shape GS into a policy that is both efficient and safe it is crucial to understand which 
factors are most important for patients’ trust in GS. 
Objective: To assess Swedish patients’ level of trust in the bioequivalence of cheap and expensive generic medicines, and the 
association between trust and various factors.  
Methods: A cross-sectional study was conducted. Questionnaires were handed out at 12 community pharmacies in Sweden, selected 
through stratified sampling, between March and April 2015. The questionnaire included seven socio-demographic questions in 
addition to 18 items divided into three sections: the ‘views on generic medicine’-scale, information on and prior experiences of GS, 
financial aspects and change of color/name. Odds Ratios (ORs) were estimated applying adjusted logistic regression analyses with trust 
in the bioequivalence of generic medicines used as outcome variable and various factors as predictors. 
Results: A total of 719 patients participated (response rate 85.7%). The results show that 70.7% of the respondents’ trust that cheap 
and expensive interchangeable generic medicines are equal. Of the respondents 36.0% considered the change in appearance and 
40.8% the change in names to complicate adherence. Lower trust in the bioequivalence of generic medicines were associated with 
being female (aOR=1.82, 95%CI 1.20:2.75, p<0.01), patients perceiving that changes in product name and appearance make adherence 
more complicated (aOR=2.18, 95%CI 1.48:3.19, p<0.001), disagreeing in that GS saves money for me (the customer) (aOR=2.68, 95%CI 
1.58:4.55, p<0.001) or that GS saves money for society (aOR=3.21, 95%CI 1.46:7.08, p<0.01). 
Conclusions: Seven out of ten respondents had trust in the bioequivalence of generic medicines, and one in three considered GS to 
complicate adherence. Four factors were associated with lower trust in GS, i.e. female gender, agreeing that changes in product name 
and appearance complicates adherence, disagreeing in that GS saves money for me or disagreeing in that GS saves money for the 
society. Low trust in GS needs to be addressed, not least in the communication between health professionals and patients. 
 
Keywords 
Drugs, Generic; Drug Substitution; Health Knowledge, Attitudes, Practice; Patient Preference; Multivariate Analysis; Surveys and 
Questionnaires; Sweden 
 
INTRODUCTION 
Generic substitution (GS), the substitution of prescribed 
medicines for cheaper generic alternatives, is a cost-
containment strategy meant to contain pharmaceutical 
expenditure without compromising health objectives.1 GS 
means that patients are offered a cheaper generic medicine 
with the same amount of active substance, same formula, 
with bioequivalence demonstrated in appropriate studies 
(thereby exchangeable) instead of the prescribed product.2 
It is implemented in a wide range of countries and the 
number of off-patent medicines entering the market is 
increasing.1,3 GS was introduced in Sweden in 2002 and has 
been effective, lowering the cost of pharmaceuticals for 
patients and the government by billions (SEK) every year 
and giving Sweden among the lowest prices on off-patent 
medicines in all of Europe.4 
A high substitution rate is a desirable goal for policymakers 
as well as taxpayers to encourage competition on the 
pharmaceutical market and lower the cost of medicines. 
However, it is only a desirable goal if patients accept GS 
and trust the generics they purchase from the pharmacy. 
Patients’ experiences with GS are mixed. Nordic and 
international studies have reported that GS is well accepted 
by a majority of patients.5,6 Nevertheless, patients report 
that GS confuses and worries them, possibly resulting in 
mix-ups, double medication and non-adherence thereby 
posing a risk to patient safety.7-11 Some patients (range 8-
34%) also report reduced effect of treatment or new side 
effects from GS.5,12 Trust in the bioequivalence of generics 
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has been proven important to receive the full benefit of a 
treatment.13 Hence, patients’ perceptions of the received 
product and trust in the bioequivalence of interchangeable 
generic and brand medicines can be crucial for adherence, 
effect and side effects.13-15 
A systematic review from 2018 identified seven domains 
influencing generic use in the United States (patient-
related; formulary management and cost containment; 
Medicare and Medicaid polices; promotional activities; 
educational initiatives; technological; and physician-related 
factors). Patient-related factors were the most studied and 
discussed domain in the identified litterature16, implying its 
large role in understanding GS. Level of education, gender, 
prior experience with GS and income has been shown to 
influence patients’ acceptance of GS.5,16-21 
Recommendations, information and the perceptions of 
physicians and pharmacists have also been found 
important to patients’ experience and acceptance.7,16,22-24 
By including all those factors previously identified in one 
study, this study provides a broader knowledge base 
regarding patients’ trust in the bioequivalence of generic 
medicines. This could benefit decision makers and 
professionals involved with the development and 
improvement of the current system for GS. The aim of this 
study was to assess Swedish patients’ level of trust in the 
bioequivalence of cheap and expensive generic medicines, 
and the association between trust and various factors. 
 
METHODS 
Study design and context 
This was a cross- sectional study with data collected 
through a structured questionnaire.25  
The Swedish healthcare system is tax funded, and the 
degree of reimbursement for pharmaceuticals increases 
with patients’ expenses for prescription medicines included 
in the pharmaceutical benefits scheme.26 The patient pays 
a maximum of 2200 SEK within a period of 12 months for 
pharmaceuticals included in the pharmaceutical benefits 
scheme. All costs in excess are subsidized by the 
government until the end of the 12-month period. Based 
on clinical data from the manufacturing pharmaceutical 
company, the Swedish Medical Product Agency decides 
which pharmaceuticals with the same amount of active 
substance and same formula are to be considered 
bioequivalent and thereby interchangeable.27,28 All Swedish 
pharmacies must provide patients with the cheapest 
interchangeable product, which once a month is appointed 
by the Dental and Pharmaceutical Benefits Agency and 
referred to as “the preferred product of the month”. The 
prescriber or the pharmacist can oppose the substitution, 
for instance, on medical grounds.1 The patient can also 
choose the prescribed product or an alternative generic 
instead of the generic with the lowest price, but will then 
have to pay the price difference out of pocket. 
Sample selection 
A stratified random sampling method was used.25 All 290 
municipalities in Sweden were divided into ten strata based 
on average yearly income (per household), which has been 
shown previously to influence patient preferences 
regarding generic substitution.21 One municipality in each 
stratum was selected with the aim of representativity with 
regard to geography, size (number of inhabitants) and 
percentage of people born outside Sweden.29 In the two 
strata with the highest number of inhabitants (representing 
more than 20% of the population), two municipalities were 
selected from each, resulting in 12 municipalities in total. 
One pharmacy was selected in each municipality with the 
aim of heterogeneity in regard to placement/surrounding 
and pharmacy owner. Proportionate sampling was used to 
decide the number of questionnaires for each stratum, so 
that the number of questionnaires per strata would reflect 
the total number of individuals in each strata and hence the 
population.25 Questionnaires were hence handed out at 12 
pharmacies in 12 different municipalities located in the 
northern, middle and southern part of Sweden. Inclusion 
criteria were that participants should have previously or 
currently use prescribed medicines, at some point have 
been offered a generic substitution and speak Swedish. 
Questionnaire development  
A questionnaire was developed based on previously 
identified factors relevant to patients’ acceptance of and 
trust in generic substitution.5,17,18,20,21 The questionnaire 
included 18 items divided into three sections, in addition to 
seven questions about socio-demographics. Section 1 
consisted of the ‘views on generic medicine’- scale with 
four items developed in Danish by Rathe et al. and one 
question regarding acceptance of GS.30 The ‘views on 
generic medicine’-scale consists of questions about the 
equivalence between cheaper and more expensive generics 
in regards to safety, side-effects and effect. The Danish 
questions were translated to Swedish by the Swedish and 
Danish authors (one author is fluent in both Swedish and 
Danish) and checked by experts in the field. The two 
languages are closely related and very similar in regard to 
the four items in the scale. All items were answered on a 5-
point Likert response scale (strongly agree=5, agree=4, 
neutral=3, disagree=2, strongly disagree=1). The response 
to the four items-‘views on generic medicine’- scale 
resulted in a trust index value from 1 to 5, which measured 
to what degree the patients considered interchangeable 
generics with different price (expensive/cheap) equal 
regarding safety, side-effects and effect. From here on 
described as trust in equality. In this paper, the scale was 
reversed so that a high score equals a high level of trust 
(max=5) and a low score a low level of trust (min=1), in the 
interests of simplifying understanding of the results. An 
average trust score was calculated of the 4 items (range 1 
to 5) and dichotomized (low trust ≤3, and high trust>3) and 
applied as the outcome variable.  
Section 2 consisted of eight items concerning information 
regarding GS from physicians and pharmacists, as well as 
patients’ prior experiences with GS. Section 3 included five 
items regarding the financial aspect of GS and difficulties 
with changes in color/name. All items were answered on a 
5-point Likert response scale. Two different scales were 
used: ‘Strongly agree, agree, don’t agree or disagree’ and 
‘always, often, sometimes (half of the time), seldom, 
never’. The questions regarding socio-demography 
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included: age, gender, education level, native language, 
income, and number of medicines taken daily.  
The questionnaire was initially tested for content validity by 
three researchers with wide experience in quantitative and 
qualitative method design. Subsequently, 20 cognitive 
interviews with concurrent and retrospective ‘thinking 
aloud’ and probing were carried out with medicine users 
focusing on comprehensiveness and relevance of the 
questions as well as the appearance of the questionnaire.31 
The questions and response scales were adapted 
accordingly. All pilot respondents were shown the new 
version of the questionnaire and approved the changes. 
Last, the feasibility of the data collecting procedure and 
comprehensibility of the final questionnaire was piloted at 
two different community pharmacies. A total of 41 
questionnaires were handed out over two days to 
pharmacy customers who met inclusion criteria. Minor 
modifications were made to the layout and order of 
questions post pilot. 
Data collection 
All pharmacy owners and pharmacy managers at the 12 
pharmacies contacted regarding data collection at or near 
the pharmacy agreed to participate. Pharmacy customers 
were approached consecutively inside or next to the 
entrance of the selected pharmacies. The concept of 
generic substitution was clarified for all customers, and 
their informed consent requested before the questionnaire 
was handed out. Some customers (n=160) requested that 
data collectors read the questions to them, for example 
due to poor eyesight. Gender and approximate age were 
registered for customers declining participation. Data were 
collected during March and April 2015. The days and times 
for data collection were varied to include all types of 
customers. Data were therefore collected during all 
opening hours on weekdays as well as weekends. 
Statistical analysis 
In the analysis the following independent variables were 
used: gender, age, education level, income, native 
language, number of pharmaceuticals per day, acceptance 
of GS, information received, prior experiences with changes 
in effect/side effects, difficulties with adherence due to 
name and appearance changes and financial aspects. 
Moreover the two items regarding confusion because of 
changes in name or appearance were combined into one 
dichotomized item predicting overall confusion. All 
variables were initially analyzed descriptively. Socio-
economic characteristics and the answers to section 2-3 are 
presented descriptively and stratified according to level of 
trust.  
Crude and adjusted logistic regression analyses were 
performed. The crude association between low trust as the 
outcome variable and each of the independent variables 
Table 1. The characteristics of the study population and their average trust in the bioequivalence of cheap and expensive 
interchangeable generic medicines. The data are displayed for each level of the studied variables for all respondents and 
stratified into low (trust≤3) and high (trust>3) trust. 
Variable n (%) 
Trust value (all respondents) 
median 
mean 
(SD) 
Low trust 
n (%) 
High trust 
n (%) 
Gender      
Male 294 (40.9) 4.0 3.9 (0.9) 63 (21.4) 231 (78.6) 
Female 425 (59.1) 3.8 3.6 (1.1) 148 (34.8) 277 (65.2) 
Age      
18-35 36 (5.0) 4.0 4.0 (0.7) 4 (11.1) 32 (88.9) 
36-50 103 (14.3) 4.0 3.8 (1.0) 31 (30.1) 72 (69.9) 
51-65 207 (28.8) 3.8 3.7 (1.0) 63 (30.4) 144 (69.6) 
66-80 321 (44.7) 3.8 3.7 (1.0) 103 (32.1) 218 (67.9) 
81+ 52 (7.2) 3.8 3.8 (0.9) 10 (19.2) 42 (80.8) 
Education level      
Elementary school 144 (20) 3.5 3.5 (1.1) 56 (38.9) 88 (61.1) 
High school 232 (32.3) 4.0 3.8 (1.0) 62 (26.7) 170 (73.3) 
University 341 (47.4) 4.0 3.8 (0.9) 92 (27.0) 249 (73.0) 
Missing 2 (0.3) 3.1 3.1 (1.6) 1 (50.0) 1 (50.0) 
Income (monthly before tax)      
<10 000 SEK 71 (9.9) 3.8 3.5 (1.2) 26 (36.6) 45 (63.4) 
10 000-19 999 247 (34.4) 3.8 3.7 (1.0) 75 (30.4) 172 (69.6) 
20 000-29 999 135 (18.8) 4.0 3.8 (1.0) 34 (25.2) 101 (74.8) 
30 000-39 999 105 (14.6) 4.0 3.9 (0.9) 22 (21.0) 83 (79.0) 
40 000+ 93 (9.5) 4.3 3.9 (0.9) 23 (24.7) 70 (75.3) 
Missing 68 (9.5) 3.4 3.4 (1.2) 31 (45.6) 37 (54.4) 
Native language      
Swedish 699 (93.0) 3.8 3.8 (1.0) 195 (27.9) 474 (67.8) 
Other 45 (6.3) 3.8 3.5 (1.0) 15 (33.3) 30 (66.7) 
Missing 5 (0.7) 3.5 3.3 (1.4) 1 (20.0) 4 (80.0) 
Number of pharmaceuticals (daily)      
None 101 (14.0) 4.0 3.6 (1.1) 35 (34.7) 66 (65.3) 
1 to 2 261 (36.3) 3.8 3.8 (0.9) 66 (25.3) 195 (74.7) 
3 to 4 200 (27.8) 3.8 3.7 (1.0) 63 (16.5) 137 (68.5) 
5+ 157 (21.8) 3.8 3.7 (1.1) 47 (30.0) 110 (70.0) 
Total 719 (100.0) 3.8 3.7 (1.0) 211 (29.3) 508 (70.7) 
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was assessed through crude odds ratios (OR) with 95% 
confidence intervals (CI) applying univariable logistic 
regression. For the multivariable analysis the four items 
regarding ‘prior experiences’ were excluded due to a risk of 
overlap with questions in the trust index. The multivariable 
model was fitted by first including variables based on above 
univariate/crude analysis. Initially, variables with p-values 
<0.15 were included. In the next steps one by one, 
variables having a p-value >0.05 and implying a change less 
then <20 % in the beta coefficients by removal of the other 
variables in the remaining model were removed.32 The fit of 
the model was tested with Hosmer and Lemeshow Test.32 
 
RESULTS  
A total of 849 pharmacy customers who met the inclusion 
criteria were invited to fill out the questionnaire; 719 
agreed to participate, resulting in a response rate of 84.7%. 
The population characteristics and the median and average 
trust values are presented in Table 1. The majority of the 
participants were women (59.1%), the most common age 
group was 66-80 years old (44.7%) and most common 
education level was university or equivalent (47.4%). Half 
of the study population was currently using three or more 
medicines per day. 
Patients trust in GS (range 1 to 5) was on average 3.8 
(median) or 3.7 (mean, SD 1.0), see Table 1. The average 
Table 2. Overview of the answers to questionnaire items and average trust in the bioequivalence of cheap and expensive 
exchangeable generic medicines. Data are displayed for each level of the studied variables for all respondents and stratified on low 
(trust≤ 3) and high (trust>3) trust. 
Variable  Trust value (all respondents) 
 n (%) 
Median 
(mean) 
Low trust 
n (%) 
High trust 
n (%) 
Acceptance of generic substitution (GS)     
Sometimes/often/always Yes to GS 584 (81.2) 4.0 (4.0) 112 (19.2) 472 (80.8) 
Seldom/never Yes 126 (17.5) 2.8 (2.7) 94 (74.6) 32 (25.4) 
Missing values 9 (1.3) 3.0 (3.4) 5 (55.6) 4(44.4) 
Previous experiences     
Have experienced better effect 132 (18.4) 3.4 (3.4) 58 (43.9) 74 (56.1) 
Never experienced better effect 522 (72.6) 4.0 (3.9) 119 (22.8) 403 (77.2) 
Missing values 65 (9.0) 3.0 (3.2) 34 (52.3) 31 (47.7) 
Have experienced less effect 213 (29.6) 3.0 (3.0) 126 (59.2) 87 (40.8) 
Never experienced less effect 440 (61.2) 4.3 (4.2) 50 (11.4) 390 (88.6) 
Missing values 66 (9.2) 3.0 (3.2) 35 (53.0) 31 (47.0) 
Have experienced fewer side-effects 102 (14.2) 4.0 (3.9) 56 (54.9) 46 (45.1) 
Never experiences fewer side-effects 546 (75.9) 3.0 (3.1) 119 (21.8) 427 (78.2) 
Missing values 71 (9.9) 3.0 (3.2) 36 (50.7) 35 (49.3) 
Have experienced more side-effects 159 (22.1) 3.0 (2.9) 103 (64.8) 56 (35.2) 
Never experiences more side-effects 490 (68.2) 4.3 (4.1) 69 (14.1) 421 (85.9) 
Missing 70 (9.7) 3.0 (3.2) 39 (55.7) 31 (44.3) 
Information     
Have received info from physician 467 (65.0) 4.0 (3.7) 125 (26.8) 342 (73.2) 
Have never received info from physician 252 (35.0) 3.8 (3.7) 86 (34.1) 166 (65.9) 
Have received info from Pharm 713 (99.2) 3.8 (3.7) 209 (29.3) 504 (70.7) 
Have never received info from Pharm 6 (0.8) 3.50 (3.5) 2 (33.3) 4 (66.7) 
Have received info from physician and Pharm 465 (64.7) 4.0 (3.8) 124 (26.7) 341 (73.3) 
Never received info from physician or Pharm 4 (0.6) 3.6 (3.6) 1 (25.0) 3 (75.0) 
Confusion     
Change in appearance complicates adherence     
Strongly agree/agree 259 (36.0) 3.5 (3.6) 97 (37.5) 162 (62.5) 
Neutral/disagree/strongly disagree 458 (63.7) 4.0 (3.8) 112 (24.5) 346 (75.5) 
Missing values 2 (0.3) 2.1 (2.1) 2 (100.0) 0 
Change in names complicates adherence     
Strongly agree/agree 293 (40.8) 3.5 (3.5) 115 (39.2) 178 (60.8) 
Neutral/disagree/strongly disagree 424 (59.0) 4.0 (3.9) 94 (22.2) 330 (77.8) 
Missing values 2 (0.3) 2.1 (2.1) 2 (100.0) 0 
Financial aspects      
GS saves money for me (the customer)     
Strongly agree/agree/neutral 623 (86.6) 4.0 (3.8) 159 (25.5) 464 (74.5) 
Disagree/strongly disagree 95 (13.2) 3.0 (3.1) 52 (54.7) 43 (45.3) 
Missing values 1 (0.2) 4.8 (4.8) 0 1 (100) 
GS saves money for society     
Strongly agree/agree/neutral 671 (93.3) 4.0 (3.8) 179 (26.7) 492 (73.3) 
Disagree/strongly disagree 47 (6.5) 2.5 (2.8) 32 (68.1) 15 (31.9) 
Missing 1 (0.2) 5.0 (5.0) 0 1 (100.0) 
The pharmacy profits from GS     
Strongly agree/agree 116 (16.1) 3.3 (3.4) 50 (43.1) 66 (56.9) 
Neutral/disagree/strongly disagree 602 (83.7) 4.0 (3.8) 161 (26.7) 441 (73.3) 
Missing 1 (0.2) 5.0 (5.0) 0 1 (100.0) 
Pharm=Pharmacist; GS= Generic substitution 
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trust value was lower among women than among men. 
Moreover, trust decreased with increased age and number 
of pharmaceuticals. Patients with a lower education level 
and patients with lower income had a lower level of trust 
on average, see Table 1. When the total sample was 
stratified into groups of low and high trust, 70.7% of the 
respondents had high trust in the equivalence. A majority 
(82.1%) of the respondents sometimes, often or always 
accepts generic substitution, see Table 2. The trust average 
(mean) among this group was 4.0 (SD 0.9) compared to 2.8 
(SD 0.8) among those who seldom or never accept 
substitution. A majority (53.1%) of the patients with low 
trust in bioequivalence still accepted substitution 
sometimes, often or always. 
In Table 2 findings concerning information regarding GS 
from physicians and pharmacists and patients’ prior 
experiences with GS are presented. Nearly one-third 
(29.6%) of the respondents had experienced less effect 
after substitution, and 22.1% more side effects. However, 
18.4% had experienced a better effect and 14.2% fewer 
side effects. Almost all patients (99.2%) had received 
information about GS from a pharmacist at some point, 
while 65.0% had received information from a physician. 
Slightly more than one-third of the patients considered the 
change in appearance (36.0%) or name (40.8%) to 
complicate adherence. Patients with a greater number of 
medicines were overrepresented in the group that found 
GS to complicate adherence. When asked if generic 
substitution saves money for society 6.5% disagreed or 
strongly disagreed. Regarding savings on a personal level 
13.2% disagreed or strongly disagreed, see Table 2. 
The multiple logistic regression (Table 3) showed that 
women had lower trust than men (ORadjusted=1.82, 95%CI 
1.20:2.75, p<0.01), and that patients who considered GS to 
complicate adherence had a lower trust in the 
bioequivalence compared to patients who did not 
(ORadjusted=2.18, 95%CI 1.48:3.19, p<0.001). Patients 
disagreeing in that GS saves money for me (the customer) 
(ORadjusted=2.68, 95%CI 1.58:4.55, p<0.001) or that GS 
saves money for society (ORadjusted=3.21, 95%CI 
1.46:7.08, p<0.01) had lower trust, as presented in Table 3. 
The Hosmer and Lemeshow Test support fit of the model 
(p=0.92). For the crude analysis, see Online Appendix.  
 
DISCUSSION 
The aim of this study was to assess Swedish patients’ level 
of trust in the bioequivalence of cheap and expensive 
generic medicines, and the association between trust and 
various factors. Overall, the results show that a majority 
(70.7%) of the respondents’ trust that cheap and expensive 
interchangeable generic medicines are equal in regard to 
quality, effect and side-effects and that 81.2% of the 
respondents sometimes/often or always accepted GS. A 
vast majority of the respondents does believe that today’s 
system saves money for the individual and society. Out of 
the studied variables, female gender and opinions that 
changes in name and appearance make adherence more 
complicated, disagreeing in that GS saves money for me 
(the customer) or that GS saves money for society were 
seen to significantly increase the odds of low trust in the 
bioequivalence. We found no association for level of 
education, prior experience with GS (excluded in our 
adjusted analysis due to overlap with the outcome variable) 
and income, which earlier has been shown to influence 
patients’ acceptance of GS.5,16-20 However, level of 
education and income were important mediators in our 
final model.  
This study implies that the majority of Swedish patients 
(70.7%) trust in the bioequivalence of interchangeable 
generics, however almost one third of the patients have a 
low level of trust. Nevertheless, a majority (53.1%) of the 
patients with a low level of trust in the equality still 
accepted generic substitution. A Finnish questionnaire 
study found that 80.9% of patients held the opinion that 
cheaper generics are equally effective and in Denmark a 
corresponding figure was 90.4%.30,33 This result indicates 
that Swedish patients have a lower level of trust in the 
bioequivalence of cheaper generics than patients in 
Table 3. The result from the univariate and multivariate logistic regression analyses presented as odds ratios (OR) for low trust in the 
bioequivalence of cheap and expensive interchangeable generics with 95% confidence intervals (95%CI). *p<0.05 **p<0.01 ***p<0.001. 
(n=648) 
Variable 
Crude OR 
(95%CI) 
Adjusted OR
1
 
(95%CI) n=648 
Gender   
Male (ref) 1 1 
Female 1.96 (1.39:2.76)*** 1.82 (1.20:2.75)** 
Confusion   
Change in appearance/name complicates adherence   
 Neutral/disagree/strongly disagree on item 3A+3B (ref) 1 1 
 Agree/strongly agree on item 3A+3B 1.98 (1.43:2.75)*** 2.18 (1.48:3.19)*** 
Financial aspects   
 GS saves money for me (the customer)   
 Strongly agree/agree/neutral (ref) 1 1 
 Disagree/strongly disagree 3.53 (2.27:5.50)*** 2.68 (1.58:4.55)*** 
 GS saves money for society   
 Strongly agree/agree/neutral (ref) 1 1 
 Disagree/strongly disagree 5.86 (3.10:11.08)*** 3.21 (1.46:7.08)** 
1
A backward elimination stepwise selection model was performed. Only the variables included in the final model are presented. The final 
model is adjusted for education level, monthly income, age, numbers of medication, and information from the physician. Individuals 
were excluded from regression analyses if data was missing on covariates. The final adjusted model included 648 patients. 
GS= Generic substitution 
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Denmark and Finland. The system for substitution varies 
between the three countries; Denmark appoint new 
products with the lowest price every fortnight compared to 
every month in Sweden, and every three months in Finland. 
Hence, no conclusion can be drawn regarding the influence 
of the duration of price period on patients’ trust in 
bioequivalence.  
Another variable previously shown to positively influence 
patients trust in GS is the pharmaceutical counselling at the 
pharmacy.7,22-24 Pharmacists have an important role to play 
in securing the patients’ confidence in generics and 
consequently adherence to generics. As our results show, 
several factors impact the trust level, such as gender and 
opinions that changes in name and appearance make 
adherence more complicated, disagreeing in that GS saves 
money for me (the customer) or that GS saves money for 
society. Pharmacists should be aware of these factors when 
counselling patients. Potentially the ‘views on generic 
medicine’-scale could be used by pharmacists in the 
counselling session to identify patients with low trust in the 
bioequivalence of cheaper generics. Pharmacists need to 
be both knowledgeable about generics and transfer this 
information to patients. In addition, they need to use 
counselling skills, such as listening, and explore the 
individual patient’s opinion about generics.  
No comparative communication study between the Nordic 
countries exist, but in all the countries there are studies 
showing a need for increased counselling.34-38 As an 
example a Swedish study found that little or no medical 
information is given in the interaction with the patient 
during dispensing at the pharmacy.38 Still in Swedish 
pharmacies, no more time was spent on medical 
information when GS occurred even though Swedish 
pharmacists had identified GS as a complicating factor for 
adherence.39,40 Nevertheless, both in the Finnish and the 
Danish legislation it is explicit in the legal texts, that 
information about generics has to be given both in writing 
(on the label) and orally.41 There is also a specific 
requirement that Finnish pharmacists must ensure that the 
patient is aware of the fact that the generic is replacing the 
previous brand. This is not the case for the Swedish 
legislation. To further explore the impact of counselling on 
trust, a Nordic comparative study is warranted.  
The results also showed that about 30% have experienced 
less effect compared to about 20% who had experienced a 
better effect from their medication after a substitution. In 
addition, almost 25% of patients reporting more side 
effects compared to 14% of participants reporting fewer 
side effects. This is in line with previous studies reporting 
changes in effect and/or side effects after 
substitution.5,7,8,12 However, to the best of our knowledge 
no one has previously studied occurrence of better effect 
and fewer side effects after GS. 
Over one third of patients considered GS to complicate 
adherence, this was also associated with lower trust in the 
bioequivalence. Lower adherence due to changes in 
medicine appearances after GS has previously been shown 
by Kesselheim et al.11,42 Requirements regarding equal 
appearance for all generics that are to be substituted could 
prevent unintentional interruption in medication use and 
mix ups. In Sweden there are no requirements regarding 
appearance in order for approval of bioequivalence (except 
for differences in size) and substitution.43 Hence, GS can 
result in differences in e.g. color of the medicine. In this 
way, current legislation does not support patients’ use of 
medicine in this regard, thereby potentially causing GS to 
complicate adherence. This could compromise the outcome 
of the treatment and hence needs to be addressed, also in 
the communication between health professionals and 
patients. 
In this study, females have lower trust in GS compared to 
men, which is also reported elsewhere.6,17-20 Women often 
view themselves as more sensitive to medicines compared 
to men.44,45 This might have consequences for their trust in 
GS, making them more sensitive to side effects and 
effects/no-effects of generics. They also have slightly 
different health behavior compared to males. For example, 
females tend to use more medicines compared to men.46 
They also seek more information about medicines.47,48 
Depending on what information they seek and find this 
could either make them more reluctant or more positive to 
GS.  
To conclude, although rigid requirements exist regarding 
the demonstration of bioequivalence in order to be eligible 
for GS27,28,49, many patients still distrust that cheap and 
expensive generics are equal in regard to quality, effect and 
side-effects. With this study design, it is not possible to 
determine the direction of the causality between low level 
of trust and experienced differences. Still distrust in 
equality are noteworthy as patients’ perceptions of 
received product and trust in the bioequivalence of 
generics and brand medicines has been found to be crucial 
for adherence, received effect and side effects.13-15 This 
suggests that it is this important for health professionals 
and authorities to be aware of low trust among some 
patients as well as adherence challenges after GS. Health 
care professionals need to keep this in mind when 
communicating with patients, in order to provide the 
support needed to prevent non-adherence and feelings of 
insecurity among patients. Also, physicians or pharmacists 
have the option to refuse GS for patients in risk of mix-ups. 
It can however affect the cost of the prescribed medicine 
for the patient and availability since the pharmacy might 
not have all generics in stock. Further, many refusals of 
substitution could not only result in a direct increase of 
costs for the patient, but could also affect prices generally 
due to a reduced market share for the preferred product of 
the month. Guided by the result from this study authorities 
and policy makers should reflect on whether the 
requirements for substitution are sufficient, as changes in 
colors and names can complicate patient adherence. With 
limited resources available, the best choice for the 
individual patient and for society must always be weighed 
in order to achieve a fair and cost-efficient healthcare 
system that does not compromise health objectives.  
The method used had two primary strengths. First, since 
questionnaires were handed out by a data collector 
according to a predetermined procedure, all respondents 
received the same information and were able to ask 
questions if any uncertainties arose with regard to 
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questions.50 Second, there was a high response rate 
(84.7%). However, some limitations need to be mentioned. 
The labor-intensive method of having data collectors hand 
out the questionnaires kept the number of pharmacies 
where data were collected quite low (n=12) which could 
have affected the representability. While the gender 
distribution in the study population was similar to the 
population medicine users in Sweden51, there was an 
underrepresentation of young medicine users and people 
in the lowest income level29,47, and an overrepresentation 
of people with a university degree or equivalent.29 
Customers who declined participation most often gave lack 
of time as a reason, but some stated that they did not like 
questionnaires in general. The customers who declined to 
participate represented the study population as well as the 
population of medicine users with regard to gender 
distribution and estimated age. The ‘views on generic 
medicines’ scale has been used for Danish patients prior to 
this study. When changing the dichotomization as originally 
presented in Rathe et al., including index 3 (neither trust 
nor distrust) into the ‘high trust’ group, 80% of the 
respondents in this study trusted in GS compared with 90% 
of Danish patients.30 Further the translation process can 
have resulted in divergence from the original language. As 
all participants were explained the concept of generic 
medicines and the word bioequivalence was not used, the 
internal validity was secured. A cross-sectional design also 
limits the ability to draw any casual interference of the 
identified relationships. Here a longitudinal design is 
warranted. 
 
CONCLUSIONS 
Seven out of ten respondents trusted the bioequivalence of 
generic medicines, and one in three considered GS to 
complicate adherence. In addition, four factors were 
associated with lower trust in GS i.e. female gender, 
agreeing with changes in product name and appearance 
complicates adherence, disagreeing in that GS saves money 
for me and disagreeing in that GS saves money for the 
society. Low trust in GS needs to be addressed, not least in 
the communication between health professionals and 
patients. More than one in three respondents considered 
the changes in name or appearance to complicate their 
adherence, and about one-third had experienced a change 
in effect and number of side effects after a substitution. 
This could compromise the outcome of the treatment. It is 
important that health professionals are attentive to, 
prevent and address nonadherence, especially after GS.  
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